Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors

Laura S. Wood; Harvey Lemont; Aminah Jatoi; Mario E. Lacouture; Caroline Robert; Karen Keating; Roger Anderson

doi:10.1016/S1548-5315(11)70385-0

Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors

Laura S. Wood, Harvey Lemont, Aminah Jatoi, Mario E. Lacouture, Caroline Robert, Karen Keating, Roger Anderson

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

22 Citations (Scopus)

Résumé

Multikinase inhibitors (MKIs, eg, sorafenib and sunitinib) are oral anticancer agents associated with handfoot skin reaction (HFSR), a cutaneous adverse event affecting 20%-40% of patients treated with these drugs. Although usually mild, symptoms of HFSR can evolve into a painful condition, resulting in a shortened duration or intensity of cancer treatment. An international, interdisciplinary panel of experts recently provided the first consensus recommendations for the management of MKI-associated HFSR.

langue originale	Anglais
Pages (de - à)	23-29
Nombre de pages	7
journal	Community Oncology
Volume	7
Numéro de publication	1
Les DOIs	https://doi.org/10.1016/S1548-5315(11)70385-0
état	Publié - 1 janv. 2010

Accès au document

10.1016/S1548-5315(11)70385-0

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{c2dbf7e55142404087a7dd40c67dea28,

title = "Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors",

abstract = "Multikinase inhibitors (MKIs, eg, sorafenib and sunitinib) are oral anticancer agents associated with handfoot skin reaction (HFSR), a cutaneous adverse event affecting 20%-40% of patients treated with these drugs. Although usually mild, symptoms of HFSR can evolve into a painful condition, resulting in a shortened duration or intensity of cancer treatment. An international, interdisciplinary panel of experts recently provided the first consensus recommendations for the management of MKI-associated HFSR.",

author = "Wood, {Laura S.} and Harvey Lemont and Aminah Jatoi and Lacouture, {Mario E.} and Caroline Robert and Karen Keating and Roger Anderson",

year = "2010",

month = jan,

day = "1",

doi = "10.1016/S1548-5315(11)70385-0",

language = "English",

volume = "7",

pages = "23--29",

journal = "Community Oncology",

issn = "1548-5315",

number = "1",

}

TY - JOUR

T1 - Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors

AU - Wood, Laura S.

AU - Lemont, Harvey

AU - Jatoi, Aminah

AU - Lacouture, Mario E.

AU - Robert, Caroline

AU - Keating, Karen

AU - Anderson, Roger

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Multikinase inhibitors (MKIs, eg, sorafenib and sunitinib) are oral anticancer agents associated with handfoot skin reaction (HFSR), a cutaneous adverse event affecting 20%-40% of patients treated with these drugs. Although usually mild, symptoms of HFSR can evolve into a painful condition, resulting in a shortened duration or intensity of cancer treatment. An international, interdisciplinary panel of experts recently provided the first consensus recommendations for the management of MKI-associated HFSR.

AB - Multikinase inhibitors (MKIs, eg, sorafenib and sunitinib) are oral anticancer agents associated with handfoot skin reaction (HFSR), a cutaneous adverse event affecting 20%-40% of patients treated with these drugs. Although usually mild, symptoms of HFSR can evolve into a painful condition, resulting in a shortened duration or intensity of cancer treatment. An international, interdisciplinary panel of experts recently provided the first consensus recommendations for the management of MKI-associated HFSR.

UR - http://www.scopus.com/inward/record.url?scp=77649213517&partnerID=8YFLogxK

U2 - 10.1016/S1548-5315(11)70385-0

DO - 10.1016/S1548-5315(11)70385-0

M3 - Article

AN - SCOPUS:77649213517

SN - 1548-5315

VL - 7

SP - 23

EP - 29

JO - Community Oncology

JF - Community Oncology

IS - 1

ER -